SG11202003556UA - Compositions of phosphorylated tau peptides and uses thereof - Google Patents
Compositions of phosphorylated tau peptides and uses thereofInfo
- Publication number
- SG11202003556UA SG11202003556UA SG11202003556UA SG11202003556UA SG11202003556UA SG 11202003556U A SG11202003556U A SG 11202003556UA SG 11202003556U A SG11202003556U A SG 11202003556UA SG 11202003556U A SG11202003556U A SG 11202003556UA SG 11202003556U A SG11202003556U A SG 11202003556UA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- phosphorylated tau
- tau peptides
- peptides
- phosphorylated
- Prior art date
Links
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Marine Sciences & Fisheries (AREA)
- Psychology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762577157P | 2017-10-25 | 2017-10-25 | |
PCT/US2018/057286 WO2019084118A2 (en) | 2017-10-25 | 2018-10-24 | PHOSPHORYLATED TUBE PEPTIDE COMPOSITIONS AND USES THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202003556UA true SG11202003556UA (en) | 2020-05-28 |
Family
ID=64362628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202003556UA SG11202003556UA (en) | 2017-10-25 | 2018-10-24 | Compositions of phosphorylated tau peptides and uses thereof |
Country Status (22)
Country | Link |
---|---|
US (3) | US11958889B2 (ru) |
EP (1) | EP3700556A2 (ru) |
JP (2) | JP2021501147A (ru) |
KR (1) | KR20200077543A (ru) |
CN (2) | CN111787942B (ru) |
AR (1) | AR113792A1 (ru) |
AU (1) | AU2018355325A1 (ru) |
BR (1) | BR112020008168A2 (ru) |
CA (1) | CA3079423A1 (ru) |
CL (2) | CL2020001070A1 (ru) |
CO (1) | CO2020006073A2 (ru) |
DO (1) | DOP2020000135A (ru) |
EA (1) | EA202091012A1 (ru) |
EC (1) | ECSP20026986A (ru) |
IL (2) | IL302108A (ru) |
JO (1) | JOP20200103A1 (ru) |
MA (1) | MA50465A (ru) |
MX (1) | MX2020004338A (ru) |
PH (1) | PH12020550432A1 (ru) |
SG (1) | SG11202003556UA (ru) |
TW (2) | TW202333768A (ru) |
WO (1) | WO2019084118A2 (ru) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR113792A1 (es) | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
EA202192203A1 (ru) * | 2019-02-08 | 2021-10-20 | Ац Иммуне С.А. | СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau |
BR112021021213A2 (pt) * | 2019-04-24 | 2021-12-21 | Ac Immune Sa | Administração heteróloga de vacinas de tau |
CN114728169A (zh) * | 2019-09-23 | 2022-07-08 | 麦考瑞大学 | tau蛋白病的治疗 |
CN114901275A (zh) | 2019-12-20 | 2022-08-12 | 纳米医疗有限公司 | 可用于治疗癌症的含有Toll样受体(“TLR”)激动剂前药的配制和/或共同配制的脂质体组合物及其方法 |
US20230131808A1 (en) * | 2020-04-22 | 2023-04-27 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
US20230310561A1 (en) * | 2020-09-08 | 2023-10-05 | Osaka University | Immunogenic composition targeting phosphorylated tau protein |
KR20240042508A (ko) * | 2021-08-12 | 2024-04-02 | 얀센 파마슈티칼즈, 인코포레이티드 | 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜 |
WO2023152260A1 (en) * | 2022-02-09 | 2023-08-17 | Ac Immune Sa | Anti-alpha-synuclein therapeutic vaccines |
WO2024015611A2 (en) * | 2022-07-14 | 2024-01-18 | Vaxxinity, Inc. | Tau peptide immunogen constructs |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
DE69318420T2 (de) | 1992-12-14 | 1999-01-28 | Innogenetics Nv | Monoklonale antikörper gegen das mikrotubulusassoziierte tauprotein,hybridomen, die diese antikörper sezernieren, antigenerkennung durch diese monoklonalen antikörper und deren verwendung |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
EA003739B1 (ru) | 1997-12-03 | 2003-08-28 | Байоджен, Инк. | Гидрофобно-модифицированные белки, способы их получения и их применение |
US6314469B1 (en) | 1999-02-26 | 2001-11-06 | I-Dns.Net International Pte Ltd | Multi-language domain name service |
US20050221391A1 (en) | 2000-07-11 | 2005-10-06 | Peter Davies | Reagents and methods for identification of binding agents |
GB0114719D0 (en) | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
AU2003203079B8 (en) * | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
EP2330113B1 (en) | 2002-04-19 | 2016-06-29 | The Governing Council Of The University Of Toronto | Immunological methods and compositions for the treatment of Alzheimer's disease |
WO2004058239A1 (en) | 2002-12-24 | 2004-07-15 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
WO2005058137A2 (en) | 2003-12-12 | 2005-06-30 | University Of Washington | Catheterscope 3d guidance and interface system |
US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
WO2005080986A1 (en) | 2004-02-18 | 2005-09-01 | University Of Iowa Research Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
WO2006121656A2 (en) | 2005-05-05 | 2006-11-16 | Merck & Co., Inc. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
EP1959991B1 (en) | 2005-12-12 | 2013-03-20 | AC Immune S.A. | Therapeutic vaccine |
WO2007098607A1 (en) | 2006-03-03 | 2007-09-07 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-sod1 mediated diseases |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
WO2008140639A2 (en) | 2007-02-08 | 2008-11-20 | Oligomerix, Inc. | Biomarkers and assays for alzheimer's disease |
EP2210901A4 (en) | 2007-10-19 | 2012-04-25 | Immunas Pharma Inc | ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO OLIGOMER A, AND USE THEREOF |
JP5559789B2 (ja) | 2008-08-07 | 2014-07-23 | マーシア・ファーマ・インコーポレイテッド | アルツハイマー病の処置のための免疫治療組成物 |
AU2010208181B2 (en) | 2009-01-30 | 2015-04-30 | Presympto, Inc. | Conformationally dynamic peptides |
US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
JP2012520852A (ja) * | 2009-03-18 | 2012-09-10 | エーシー イミューン ソシエテ アノニム | 治療的使用のための方法 |
UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
EP2440234A4 (en) | 2009-06-10 | 2013-11-06 | Univ New York | IMMUNOLOGICAL TARGETING OF PATHOLOGICAL TAU PROTEINS |
KR20130127547A (ko) * | 2009-07-30 | 2013-11-22 | 화이자 백신스 엘엘씨 | 항원성 타우 펩타이드 및 이의 용도 |
CA2774173A1 (en) | 2009-09-14 | 2011-03-17 | Banyan Biomarkers, Inc. | Micro-rna, autoantibody and protein markers for diagnosis of neuronal injury |
US9193969B2 (en) | 2010-04-19 | 2015-11-24 | Nlife Therapeutics, S.L. | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types |
EP3527220A1 (en) * | 2010-08-12 | 2019-08-21 | AC Immune S.A. | Vaccine engineering |
US9687447B2 (en) | 2010-10-26 | 2017-06-27 | Ac Immune S.A. | Method for preparing liposome-based constructs |
GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
EP2758433B1 (en) | 2011-09-19 | 2017-10-18 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease |
US20140314837A1 (en) | 2011-09-23 | 2014-10-23 | Ac Immune S. A. | Vaccine Therapy |
KR101976229B1 (ko) | 2011-10-21 | 2019-05-07 | 미쯔비시 케미컬 주식회사 | 주기표 제 13 족 금속 질화물 반도체 결정의 제조 방법, 및 그 제조 방법에 의해 제조되는 주기표 제 13 족 금속 질화물 반도체 결정 |
EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
US20170368167A9 (en) * | 2012-08-21 | 2017-12-28 | The Institute For Molecular Medicine | Compositions and methods related to neurological disorders |
US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
EP3104870A4 (en) | 2014-02-14 | 2017-09-13 | Ipierian, Inc. | Tau peptides, anti-tau antibodies, and methods of use thereof |
AU2015279089B2 (en) | 2014-06-26 | 2021-01-28 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
PE20180317A1 (es) | 2015-06-05 | 2018-02-09 | Genentech Inc | Anticuerpos anti-tau y metodos de uso |
US20170037004A1 (en) | 2015-07-13 | 2017-02-09 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
CN108024698B (zh) | 2015-08-14 | 2020-09-15 | 直观外科手术操作公司 | 用于图像引导外科手术的配准系统和方法 |
WO2017191560A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
KR102587130B1 (ko) | 2016-12-07 | 2023-10-11 | 제넨테크, 인크. | 항-타우 항체 및 이의 이용 방법 |
AR113792A1 (es) | 2017-10-25 | 2020-06-10 | Janssen Pharmaceuticals Inc | Composiciones de péptidos tau fosforilados y sus usos |
CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
EA202192203A1 (ru) * | 2019-02-08 | 2021-10-20 | Ац Иммуне С.А. | СПОСОБ БЕЗОПАСНОГО ВВЕДЕНИЯ ВАКЦИНЫ ФОСФОРИЛИРОВАННОГО ПЕПТИДА Tau |
BR112021021213A2 (pt) | 2019-04-24 | 2021-12-21 | Ac Immune Sa | Administração heteróloga de vacinas de tau |
-
2018
- 2018-10-24 AR ARP180103100A patent/AR113792A1/es unknown
- 2018-10-24 KR KR1020207014520A patent/KR20200077543A/ko not_active Application Discontinuation
- 2018-10-24 EA EA202091012A patent/EA202091012A1/ru unknown
- 2018-10-24 JO JOP/2020/0103A patent/JOP20200103A1/ar unknown
- 2018-10-24 WO PCT/US2018/057286 patent/WO2019084118A2/en unknown
- 2018-10-24 BR BR112020008168-0A patent/BR112020008168A2/pt unknown
- 2018-10-24 MX MX2020004338A patent/MX2020004338A/es unknown
- 2018-10-24 TW TW112117496A patent/TW202333768A/zh unknown
- 2018-10-24 CA CA3079423A patent/CA3079423A1/en active Pending
- 2018-10-24 US US16/757,621 patent/US11958889B2/en active Active
- 2018-10-24 CN CN201880083892.2A patent/CN111787942B/zh active Active
- 2018-10-24 MA MA050465A patent/MA50465A/fr unknown
- 2018-10-24 IL IL302108A patent/IL302108A/en unknown
- 2018-10-24 SG SG11202003556UA patent/SG11202003556UA/en unknown
- 2018-10-24 US US16/169,215 patent/US11124552B2/en active Active
- 2018-10-24 EP EP18804745.0A patent/EP3700556A2/en active Pending
- 2018-10-24 TW TW107137586A patent/TWI827557B/zh active
- 2018-10-24 JP JP2020523284A patent/JP2021501147A/ja active Pending
- 2018-10-24 AU AU2018355325A patent/AU2018355325A1/en active Pending
- 2018-10-24 CN CN202310829637.0A patent/CN117298259A/zh active Pending
-
2020
- 2020-04-15 PH PH12020550432A patent/PH12020550432A1/en unknown
- 2020-04-16 IL IL273980A patent/IL273980A/en unknown
- 2020-04-21 CL CL2020001070A patent/CL2020001070A1/es unknown
- 2020-05-18 CO CONC2020/0006073A patent/CO2020006073A2/es unknown
- 2020-05-22 EC ECSENADI202026986A patent/ECSP20026986A/es unknown
- 2020-07-02 DO DO2020000135A patent/DOP2020000135A/es unknown
-
2021
- 2021-01-27 CL CL2021000217A patent/CL2021000217A1/es unknown
- 2021-08-19 US US17/445,419 patent/US20210388044A1/en active Pending
-
2023
- 2023-02-09 JP JP2023018374A patent/JP2023071688A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273980A (en) | Preparations of phosphorylated tau peptides and uses thereof | |
EP3704219C0 (en) | POLYPEPTIDES AND COMPOSITIONS CONTAINING SUCH POLYPEPTIDES | |
HK1252870A1 (zh) | Sirp多肽組合物和使用方法 | |
IL265796A (en) | Preparations comprising short peptides derived from pedf and their uses | |
IL271275A (en) | Preparations containing coronas and their uses | |
EP3688011A4 (en) | PEPTIDE COMPOSITIONS AND METHOD FOR THEIR USE | |
EP3642219A4 (en) | PEPTIDE COMPOSITIONS AND RELATED PROCEDURES | |
HK1251979A1 (zh) | 肽組合物和使用方法 | |
ZA202003387B (en) | Antimicrobial peptides and methods of using same | |
EP3518910A4 (en) | MIDODRIN COMPOSITIONS AND METHOD OF USE THEREOF | |
SG11202003624SA (en) | Tau peptide immunogen constructs | |
EP3307081A4 (en) | LECITHIN COMPOSITIONS AND METHOD FOR THE PRODUCTION AND USE OF SUCH LECITHIN COMPOSITIONS | |
EP3585412A4 (en) | STABLE PEPTIDIC COMPOSITIONS | |
GB2546439B (en) | Ezrin-derived peptides and pharmaceutical compositions thereof | |
GB201712592D0 (en) | Novel compositions and uses thereof | |
EP3399990A4 (en) | THERAPEUTIC COMPOSITIONS WITH PEPTIDES AND USES THEREOF | |
EP3270985A4 (en) | Polypeptide compositions and methods of using the same | |
IL272080A (en) | Derivation of a peptide and a pharmaceutical preparation containing it | |
EP3247801A4 (en) | Ribosome-mediated incorporation of peptides and peptidomimetics | |
GB201701750D0 (en) | Peptides and nematicidal compositions | |
GB201812952D0 (en) | Compositions and uses thereof | |
GB201709731D0 (en) | Probiotic compositions and uses thereof | |
GB201700542D0 (en) | Probiotic compositions and uses thereof |